0000000000745314

AUTHOR

Maricruz Gutierrez-brito

showing 2 related works from this author

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

2010

Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the over…

Malemedicine.medical_specialtyMeasles-Mumps-Rubella VaccineInfluenza vaccineAntibodies ViralVaccines AttenuatedRubellaMeaslesDrug IncompatibilityPlacebosRubella vaccineInternal medicineInfluenza HumanmedicineLive attenuated influenza vaccineHumansVaccines CombinedMumpsAdministration IntranasalRubellaGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessMeasles-Mumps-Rubella Vaccinemedicine.drugMeaslesVaccine
researchProduct

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

2013

Background: The 7-valent pneumococcal conjugate vaccine (PCV7) has demonstrated effectiveness against pneumococcal illnesses when administered as 3 infant doses plus a toddler dose (3+1 schedule) or as an abbreviated schedule of 2 infant doses plus a toddler dose (2+1 schedule). The 13-valent pneumococcal conjugate vaccine (PCV13) is approved and World Health Organization-prequalified for administration in a 2+1 schedule when used as part of routine immunization programs. Objective: To summarize immunologic responses elicited by PCV13 administered in a 2+1 schedule and following 2 doses in a 3+1 schedule. Methods: Studies were double-blind, randomized, active-controlled, multicenter studies…

MaleSerotypePCV132+12+1; Immune response; PCV13; Pediatric; Pneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal conjugate vaccinePneumococcal VaccinesDouble-Blind MethodHumansMedicineDosingToddlerImmune responseMexicoPediatricGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryImmunogenicityPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfantAntibodies BacterialUnited KingdomClinical trialInfectious DiseasesItalySpainImmunoglobulin GConcomitantImmunologybiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drug
researchProduct